| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
HIV transcription is inhibited with low transcription when 8 μM of virally activated PBMC from HIV-infected patients are used for 2 days [1]. Treatment with ZL0580 (10 μM) increases HIV or baseline transcription through PMA [1]. [1]
|
|---|---|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: HIV-infected human CD4+ T cells. Tested Concentrations: 0-8μM. Incubation Duration: 2 days. Experimental Results: Suppression of HIV in primary CD4+ T cells. A single treatment (8 μM) resulted in an almost complete loss of productive HIV infection in CD4+ T cells. RT-PCR[1] Cell Types: PBMC from viremic HIV-infected patients. Tested Concentrations: 8μM. Incubation Duration: 2 days. Experimental Results: HIV transcription was inhibited ex vivo in PBMCs from viremic HIV-infected individuals. Cytotoxicity assay [1] Cell Types: J-Lat cells. Tested Concentrations: 0-80 μM. Incubation Duration: 1 day and 3 days. Experimental Results: Concentrations below 40 μM did not cause significant cell death. Treatment of J-Lat cells with ZL0580 (10 μM) also did not result in significant cell death at days 2, 7, and 14 compared to NC in PMA-activated and unstimulated cells. |
| References |
| Molecular Formula |
C25H23F3N4O4S
|
|---|---|
| Molecular Weight |
532.534734964371
|
| Exact Mass |
532.139
|
| CAS # |
2377151-10-3
|
| PubChem CID |
139524511
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.9
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
37
|
| Complexity |
889
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
S(C1C=CC(=CC=1)NC(NC1C=CC(C(F)(F)F)=CC=1)=O)(N1CCC[C@H]1C(NC1C=CC=CC=1)=O)(=O)=O
|
| InChi Key |
DKFYGSWCJGXEJY-QFIPXVFZSA-N
|
| InChi Code |
InChI=1S/C25H23F3N4O4S/c26-25(27,28)17-8-10-19(11-9-17)30-24(34)31-20-12-14-21(15-13-20)37(35,36)32-16-4-7-22(32)23(33)29-18-5-2-1-3-6-18/h1-3,5-6,8-15,22H,4,7,16H2,(H,29,33)(H2,30,31,34)/t22-/m0/s1
|
| Chemical Name |
(2S)-N-phenyl-1-[4-[[4-(trifluoromethyl)phenyl]carbamoylamino]phenyl]sulfonylpyrrolidine-2-carboxamide
|
| Synonyms |
ZL-0580; ZL 0580
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~469.46 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.91 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8778 mL | 9.3891 mL | 18.7783 mL | |
| 5 mM | 0.3756 mL | 1.8778 mL | 3.7557 mL | |
| 10 mM | 0.1878 mL | 0.9389 mL | 1.8778 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
